We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+9.51%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$470M
AUM Growth
+$131M
Cap. Flow
+$115M
Cap. Flow %
24.5%
Top 10 Hldgs %
48.76%
Holding
67
New
21
Increased
15
Reduced
13
Closed
12

Top Buys

1
TSRO
TESARO, Inc.
TSRO
+$15.9M
2
FXF icon
Invesco CurrencyShares Swiss Franc Trust
FXF
+$12.3M
3
ECYT
Endocyte, Inc. Common Stock
ECYT
+$10.3M
4
ZGNX
Zogenix, Inc.
ZGNX
+$10.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$10M

Top Sells

1
MRSN
Mersana Therapeutics
MRSN
+$10.7M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$10.2M
3
ARWR icon
Arrowhead Research
ARWR
+$9.52M
4
IMMU
Immunomedics Inc
IMMU
+$8.67M
5
EXEL icon
Exelixis
EXEL
+$8.61M

Sector Composition

1 Healthcare 68.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SPPI
51
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$793K 0.17%
47,200
+18,200
+63% +$394K
INSM icon
52
Insmed
INSM
$23.5B
$526K 0.11%
+26,000
New +$587K
MOTS
53
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$510K 0.11%
333
– –
GBT
54
DELISTED
Global Blood Therapeutics, Inc.
GBT
$456K 0.1%
12,000
-230,000
-95% -$10.2M
TGTX icon
55
TG Therapeutics
TGTX
$8.4B
$255K 0.05%
45,500
-6,500
-13% -$74.3K
ARWR icon
56
Arrowhead Research
ARWR
$10.5B
– –
-700,000
Closed -$9.52M
EXEL icon
57
Exelixis
EXEL
$14.1B
– –
-400,000
Closed -$8.61M
IOVA icon
58
Iovance Biotherapeutics
IOVA
$2.23B
– –
-360,000
Closed -$4.61M
MRSN
59
DELISTED
Mersana Therapeutics
MRSN
– –
-24,000
Closed -$10.7M
PBYI icon
60
Puma Biotechnology
PBYI
$434M
– –
-14,000
Closed -$828K
TECX
61
Tectonic Therapeutic
TECX
$615M
– –
-19,167
Closed -$6.57M
ACOR
62
DELISTED
Acorda Therapeutics
ACOR
– –
-275
Closed -$947K
LCI
63
CALL
DELISTED
Lannett Company, Inc.
LCI
– –
-500
Closed -$520K
LCI
64
DELISTED
Lannett Company, Inc.
LCI
– –
-62,500
Closed -$3.4M
ADMS
65
DELISTED
Adamas Pharmaceuticals
ADMS
– –
-295,000
Closed -$7.62M
BOLD
66
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-125,000
Closed -$4.78M
BHVN
67
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-2,000
Closed -$122K
1 2
3

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Ghost Tree Capital held 67 positions worth $470M, up 38% from $340M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Ghost Tree Capital deployed $115M of net new capital in Q3 2018, opening 21 new positions and adding to 15 existing holdings. Its largest new stake was TESARO, Inc.: 450,000 shares worth $17.6M.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 84% a quarter earlier.

On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $10.2M trimmed.

  • Ghost Tree Capital's largest Q3 2018 buy was TESARO, Inc.: 450,000 shares worth $17.6M.
  • Ghost Tree Capital added most to Endocyte, Inc. Common Stock in Q3 2018, an estimated $10.3M increase.
  • Ghost Tree Capital's biggest Q3 2018 reduction was Global Blood Therapeutics, Inc., cutting an estimated $10.2M.
  • Ghost Tree Capital fully exited Mersana Therapeutics in Q3 2018, selling an estimated $10.7M.
  • Ghost Tree Capital's ten largest holdings make up 49% of its $470M portfolio in Q3 2018.
  • Ghost Tree Capital opened 21 new positions and closed 12 in Q3 2018.
  • Ghost Tree Capital's portfolio value rose 38% quarter-over-quarter to $470M.

Based on Ghost Tree Capital's 13F filing for Q3 2018, filed 14 Nov 2018.